Studies on the stability of VIII:C during the manufacture of a factor VIII concentrate for clinical use.
The stability of VIII:C was investigated by monitoring samples taken at different points from a routine process for the manufacture of factor VIII concentrate and by examining the stabilising influence of a number of product formulations. Loss of VIII:C over process-finishing procedures (formulation, 0.22 micron filtration, dispensing) was associated with a citrate-induced inactivation which could be prevented by controlling the ionised calcium concentration of the solution. These results were obtained using a one-stage clotting assay but were not observed using a two-stage assay. No evidence for activation was found in vitro (e.g. by FPA generation and VIII:C stability) and the yield increase suggested by the one-stage assay was supported by results from a controlled clinical evaluation.
D000941:Antigens; D002118:Calcium / Q000494:pharmacology; D002951:Citrates / Q000494:pharmacology; D019343:Citric Acid; D004355:Drug Stability; D005169:Factor VIII / Q000627:therapeutic use; D006467:Hemophilia A / Q000628:therapy; D006801:Humans
D000941:Antigens; D002951:Citrates; D019343:Citric Acid; D005169:Factor VIII; D002118:Calcium